Share Name Share Symbol Market Type Share ISIN Share Description
Scapa Group Plc LSE:SCPA London Ordinary Share GB0007281198 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.20 -0.18% 111.60 257,954 12:04:27
Bid Price Offer Price High Price Low Price Open Price
111.60 111.80 112.80 111.00 112.20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 311.80 14.90 5.30 21.1 208
Last Trade Time Trade Type Trade Size Trade Price Currency
12:04:27 AT 684 111.60 GBX

Scapa (SCPA) Latest News

More Scapa News
Scapa Takeover Rumours

Scapa (SCPA) Discussions and Chat

Scapa Forums and Chat

Date Time Title Posts
20/8/202015:15Scapa onwards and upwards1,879
05/10/200615:18Scapa.......nobrainer or should I scarper?76
16/3/200613:43SCAPA upwards147

Add a New Thread

Scapa (SCPA) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Scapa trades in real-time

Scapa (SCPA) Top Chat Posts

Scapa Daily Update: Scapa Group Plc is listed in the Chemicals sector of the London Stock Exchange with ticker SCPA. The last closing price for Scapa was 111.80p.
Scapa Group Plc has a 4 week average price of 106p and a 12 week average price of 82.70p.
The 1 year high share price is 295p while the 1 year low share price is currently 82.70p.
There are currently 186,543,896 shares in issue and the average daily traded volume is 386,455 shares. The market capitalisation of Scapa Group Plc is £208,556,075.73.
discodave45: Hope this doesn't repeat June's share price profile.
smithless: Scuba- if they do I will be buying bucket loads. Share price depressed due to slow return to normalised trading due to Covid - all outlined in audited accounts. Depressing for those who are in, but will recover quite swiftly nxt year. Just looked at the case with Convatec and Convatec in its report and accounts under contingent liabilities fails to mention anything about its claim against Scapa being dismissed in New Jersey?!? nor that it has had to put in a new claim against Scapa? Looks like Convatec on the run a bit here.
discodave45: It's back to 2013 levels.They haven't archived annual results for March 2013 on their website but comparisons with 2015 when the share price was £2 is as follows:Rev 2015 £236m, 2020 £321m (+36%)Trading profit 2015 £18m, 2020 £28m (+56%)Adjusted eps 2015 9p, 2020 12.4p (+38%). Don't know if number of issued shares have changed since 2015, but it appears on the face of it to be well undervalued.Don't know what the forecasts are for this year but from memory brokers have 12p eps for 2021/22 (on a par with 2019/20), so again based on 2015 this should be in excess of £2 and is currently only on a forward (21/22) pe of about 7.A share that continues to baffle me! :)
marmar80: Looks like the loss of Convatec business didn't do as much damage as the share price is showing. Was down from 400 to below 200 on that announcement back in the days. Now we know that Scapa is demanding 83m+ from Convatec and officially Convatec's contra claim is rejected. Revenue up. Loss was made but promise of more to come from other businesses. For me it's a very solid update and can lead to an nice pay out in case of win against Convatec.
woodhawk: On the back of the recent strong results and with the potential of damages from Convatec, the share price really ought to be heading strongly north, back towards 300p.
marmar80: When they announced contract loss the share price tanked by 50% and still is almost 40% down.
mallorca 9: (Sharecast News) - Analysts at Berenberg slashed their target price on diversified healthcare and industrial company Scapa on Tuesday, but said the group's "positive start" to the year should restore some investor confidence. Berenberg cut its price target on the group from 520p to 300p but said that Scapa's first-quarter figures, released earlier in the day, showed that things were "not all doom and gloom" for the business, which revealed organic growth in both divisions. The bank said Scapa's first-quarter trading update was "solid", with revenues increasing 34.6% on a continuing FX basis. Berenberg noted that even when excluding Scapa's recent contract wins with ConvaTec and Systagenix, the group still delivered 3% organic growth in its industrial business and 4% in its healthcare division. "In the context of the current share price fall, we think this is a good result," said the German bank. "With positive trading and Scapa clearly confident enough about its case versus CVT (it recently decided to pursue legal action), we feel that the risk is skewed to the upside." However, Berenberg did opt to adjust its numbers to reflect lost ConvaTec revenues of £27m and underlying earnings of £13m, bringing it in line with consensus. While Berenberg lowered its price target on the company, the analysts said they still believe in Scapa's long-term story and confidently reiterated their 'buy' rating on the stock. As of 1310 BST, Scapa shares had picked up 1.45% to 168p.
aztec786: Scapa share price seems to be doin well. P/E ratio of 8 makes this a serious bargain. Thx Mallorca
kazoom: Fair enough Woody - just my view that the litigation could go either way and the share price is probably in the middle of the two outcomes; so I don't think the bad new is all in the price in this case - lose the case and further down imho. Anyway good luck with it. I'll sit and watch for now.
robow: from The Daily Telegraph Questor: money flows out of Scapa but readers should resist any temptation to join the flood Questor Inheritance Tax Portfolio: after a torrid month for the tapes maker – the loss of its boss and a big contract – things are now looking more rosy It’s been an eventful few weeks for Scapa, the maker of industrial and medical tapes tipped here in March last year at 471.4p. On May 21 it published perfectly satisfactory full-year results but unnerved the market somewhat by announcing that its chief executive, Heejae Chae, who had largely steered the company’s successful restructuring, was stepping down. Two weeks later came a much bigger bombshell: Scapa said it had received notice from a large customer, ConvaTec, that it was terminating a contract in North America worth about $30m (£24m) a year in sales. The shares lost 47pc. Then on Monday this week the company said Mr Chae had agreed to rescind his resignation and would stay on “to execute the current strategy” Keith Ashworth-Lord, who holds Scapa in his SDL UK Buffettology fund, told Questor: “The results in May were nothing other than good, but Chae’s retirement was a bolt from the blue. He is regarded as the architect of the firm in its present form and the market thought there were no succession plans. “Then, when the ConvaTec announcement came, investors put two and two together, came up with five and crucified the share price.” He added: “Last week a group of shareholders, including us, tried to get him to change his mind and convince the market that he hadn’t resigned over ConvaTec. We got the result we wanted this week and the shares have recovered to about 195p.” He said the loss of the contract was “material but not the roof falling in”. “Chae will stay until the problems are solved and that will give Scapa time to sort out the succession,” he added. “This holding has not been my finest but we are sticking with it. We bought more shares heavily after the fall – about 800,000 at various prices as low as 159p. We think it’s been an absolutely classic overreaction by the market. Personally I’m very relaxed about the whole thing.” Questor: hold Ticker: SCPA Share price at close: 199p
Scapa share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200922 11:28:42